Extracorporeal Membrane Oxygenation (ECMO) and Beyond in Near-Fatal Asthma
Abstract:
Near-fatal asthma (NFA) is a life-threatening condition that sometimes proves refractory to conventional therapies, including mechanical ventilation. This comprehensive review examines the role of extracorporeal membrane oxygenation (ECMO) and extracorporeal CO₂ removal (ECCO₂R) as rescue therapies in NFA. It synthesizes registry data, observational studies, and case series to evaluate survival outcomes, complications, and clinical implications.
Key Insights:
- NFA is defined as asthma exacerbations requiring ICU-level care, often with invasive ventilation; mortality in intubated patients ranges from 6.5% to 10.3%, but in some series rises up to 30% .
- Two phenotypes exist: rapid-onset NFA, often allergen- or stress-triggered with abrupt respiratory failure; and slow-onset NFA, often infection-driven, with progressive worsening and higher hypercapnia .
- Risk factors for NFA include prior ICU admissions, hypercapnia/acidosis, corticosteroid non-adherence, psychiatric illness, food allergy, poverty, and viral or fungal respiratory infections .
- ECMO, particularly venovenous (V–V) ECMO, provides efficient CO₂ removal and lung rest; ELSO registry analyses show survival rates of 83–95% in NFA, making asthma one of the most favorable ECMO indications .
- Post-ECMO initiation, ventilator pressures and FiO₂ requirements improve substantially, enabling ultra-protective ventilation and adjunctive procedures such as bronchoscopy .
- Complications are frequent, with hemorrhage (28%), infection (16%), renal (27%), and neurologic events (5%) reported; hemorrhage is the strongest predictor of mortality on ECMO .
- ECCO₂R, requiring lower blood flow and less invasive cannulation, has been used in severe asthma cases with safety demonstrated in observational studies, but outcomes are less well-defined than with ECMO .
- Registry data (ELSO, NHS) confirm that asthma patients supported with ECMO have better outcomes than patients with ARDS or pneumonia, with survival up to 95% vs ~70% .
- ECMO in NFA allows gradual correction of severe acidosis and hypercapnia, reduces intrathoracic pressure, and permits airway clearance procedures not possible otherwise .
- Despite excellent outcomes, no formal guidelines exist for ECMO in asthma; evidence is limited to retrospective and registry studies, highlighting the need for standardized protocols and systematic reporting .
Conclusion:
ECMO provides a lifesaving option in NFA refractory to conventional management, with survival exceeding 80% in most cohorts. ECCO₂R is a promising but less studied alternative. Given the rarity of cases, multicenter registry reporting remains essential to define best practices and improve access to these advanced therapies.
Take-Home for Clinicians: Asthma is among the most favorable indications for ECMO, with survival rates higher than for ARDS or pneumonia. Early referral to ECMO-capable centers should be considered when severe hypercapnia and acidosis persist despite maximal conventional therapy.
Discussion Question: Should ECMO be formally integrated into international asthma management guidelines for refractory NFA, given its consistently superior survival outcomes?
Take Advantage of This Resource
I encourage you to explore this growing library of articles and leverage it to stay informed on the latest in critical care. Visit the collection today at: https://perfusfind.com/ic/
This is another step in making high-quality, evidence-based information easily accessible to the critical care community. As always, thank you for your continued support!
As always, don’t forget to like, share, and subscribe. See you on the other side!
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
